PAS
TAK icon

Point72 Asia (Singapore)’s Takeda Pharmaceutical TAK Stock Holding History

Point72 Asia (Singapore)’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$40 – 1185
2024
Q4 		$40 Buy
+3
New +$41 ﹤0.01% 825

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Point72 Asia (Singapore)'s TAK Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 3 shares — an estimated $40 sold.

Point72 Asia (Singapore) first reported a position in TAK in Q4 2024 and held it in 1 quarter. The position peaked at $40 in Q4 2024. 307 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 3 Takeda Pharmaceutical shares in Q1 2025, an estimated $40.
  • Point72 Asia (Singapore) first reported a position in Takeda Pharmaceutical in Q4 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Takeda Pharmaceutical position peaked at $40 in Q4 2024.
  • 307 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.